Navuliu monoantigen (Odivo) joint Ipitaph monoantigen has been approved by the European Commission for first-line treatment for patients with renal cell carcinoma

recently, Baishi MeishiBao announced that Navuliyu monoantigen (Odivo) 3 mg/kg joint Ipitano 1 mg/kg ("low dose") program has been approved by the European Commission for the first-line treatment of patients with advanced stage renal cell carcinoma (RCC) patientsOpdivo ® (OdivoTM)OdivoTM is a PD-1 immune checkpoint inhibitor that uniquely uses the body's own immune system to help the body recover its anti-tumor immune responseThis trait, which uses the body's own immune system to fight cancer, has made OdivoTM an important treatment option for many types of tumorsbased on its scientific expertise in I-O treatment, O'DeVos has a world-leading research and development program covering phase 3clinicaltrial spree(http://, including Phase III clinical trials, in a variety of tumor typesto date, more than 25,000 patients have been enrolled in OdyvoTM's clinical research and development programThe clinical trials of OdivoTM have helped to better understand the potential cue effects of biomarkers on patient treatment options, in particular identifying how patients with different Levels of PD-L1 expression can benefit from OdivoTMthe results of theof the relevant studies are based on the results of a clinical study in Phase 214 Of CheckMate." The trial was terminated prematurely after the planned mid-termanalysis(http://Analysis showed that Navuliyu monoantigen and low-dose epimutine monoantigen combination therapy can significantly improve OSThe risk of death in middle- and high-risk patients was reduced by 37% compared to the current standard treatment plan, Sconetinib (HR 0.63; 99.8% CI: 0.44 to 0.89; p 0.0001OS benefits were observed regardless of PD-L1 expression levels So far, the median total survival of patients receiving Navuliyu monoantigen combination low-dose Epimamono-resistant treatment has not yet reached (95% CI: 28.2 months to non-assessable (NE)), while the median total survival of the Shunitreat treatment group was 25.9 months at the same time, , the Navuliyu monoantigen combined low-dose Epima monoantigen programme showed a higher objective remission rate of 41.6% (95% CI: 36.9 to 46.5; p 0.0001; n?177/425), sconeini 26.5% (95% CI: 22.4 31.0; n?12.42 to 42 The total remission rate was 9.4% in the Navuliyu monoantigen and low-dose Epimamono-resistant combination therapy group, compared with 1.2% in the Schonitinib group in patients who received Navuliyu monoantigen and low-dose epithelial treatment had not yet reached the median remission time (95% CI: 21.8 months to NE), and the Schonitinib group was 18.2 months (95% CI: 14.8 months to NE) In addition, Navuliyu monoantigen and low-dose epimuta combination therapy were less of a level 3 or 4 adverse event (65 percent vs 76%)than the curatini therapy